Peginterferon beta-1a

Peginterferon beta-1a', sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

Peginterferon beta-1a
Clinical data
Trade namesPlegridy, Plegridy Pen
AHFS/Drugs.comMonograph
MedlinePlusa614059
License data
Pregnancy
category
  • AU: D [1]
  • US: C (Risk not ruled out) [1]
    Routes of
    administration    		Subcutaneous injection
    Drug classAntineoplastic agent
    ATC code
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    DrugBank
    UNII
    KEGG
    Chemical and physical data
    FormulaC913H1417N246O256PS7 [C2H4O]n
    Molar mass44000

    The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[2][3]

    Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[4][2]

    Medical uses

    In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[3]

    In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[2]

    References
    1. "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.
    2. "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    3. "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.
    4. "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.